Editorial
doi: 10.1016/j.jval.2011.10.001.
Epub 2011 Nov 12.
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia
- PMID: 22152174
- DOI: 10.1016/j.jval.2011.10.001
Item in Clipboard
Editorial
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia
Value Health.
2011 Dec.
Free article
No abstract available
Comment on
-
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.Value Health. 2011 Dec;14(8):1057-67. doi: 10.1016/j.jval.2011.07.006. Epub 2011 Oct 12. Value Health. 2011. PMID: 22152175
Similar articles
-
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.Value Health. 2011 Dec;14(8):1057-67. doi: 10.1016/j.jval.2011.07.006. Epub 2011 Oct 12. Value Health. 2011. PMID: 22152175
-
Even better kinase inhibitors for chronic myeloid leukemia.N Engl J Med. 2010 Jun 17;362(24):2314-5. doi: 10.1056/NEJMe1004430. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525994 No abstract available.
-
Second-generation BCR-ABL kinase inhibitors in CML.N Engl J Med. 2010 Oct 21;363(17):1672-3; author reply 1673-5. doi: 10.1056/NEJMc1007927. N Engl J Med. 2010. PMID: 20973144 No abstract available.
-
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27. Clin Ther. 2012. PMID: 22285209 Review.
-
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.Cancer. 2010 Mar 15;116(6):1419-30. doi: 10.1002/cncr.24928. Cancer. 2010. PMID: 20120030 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
